Results 41 to 50 of about 2,590,210 (272)

Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients

European Journal of Translational Myology, 2022
We conducted a cross-sectional study to evaluate the role of serum levels of CA125 and HE4 in predicting optimal cytoreductive surgery. Eligible women who had been diagnosed with ovarian cancer based on both clinical and imaging criteria were enrolled ...
Elham Saffarieh, Setare Nassiri, Majid Mirmohammadkhani   +2 more
doaj   +1 more source

Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis.

Journal of Clinical Oncology, 2019
PURPOSE Gastric cancer (GC) with peritoneal metastases (PMs) is a poor prognostic evolution. Cytoreductive surgery (CRS) yields promising results, but the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) remains controversial. Here we aimed to
P. Bonnot, G. Piessen, V. Kepenekian, E. Decullier, M. Pocard, B. Meunier, J. Bereder, K. Abboud, F. Marchal, F. Quénet, D. Goéré, S. Msika, C. Arvieux, N. Pirró, R. Wernert, P. Rat, J. Gagnière, J. Lefèvre, T. Courvoisier, R. Kianmanesh, D. Vaudoyer, M. Rivoire, P. Meeus, G. Passot, O. Glehen   +24 more
semanticscholar   +1 more source

Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline.

Current Oncology, 2020
Objective The purpose of the present review was to provide evidence-based guidance about the provision of cytoreductive surgery (crs) with hyperthermic intraperitoneal chemotherapy (hipec) in the treatment of peritoneal cancers.
R. Auer, D. Sivajohanathan, J. Biagi, J. Conner, E. Kennedy, T. May   +5 more
semanticscholar   +1 more source

Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta‐analysis

Colorectal Disease, 2020
Peritoneal metastases from colorectal cancer confer the worst survival among all metastatic sites. The adoption of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can offer selected patients with isolated colorectal ...
V. Narasimhan, Sabrina Tan, Joseph C. H. Kong, T. Pham, M. Michael, R. Ramsay, S. Warrier, A. Heriot   +7 more
semanticscholar   +1 more source

Remote results of treatment of patients with advanced ovarian cancer after interval and delayed cytoreductive surgery: a retrospective single-center study

Опухоли женской репродуктивной системы
Background. Neoadjuvant chemotherapy is an option for the treatment of advanced ovarian cancer. The data about optimal chemotherapy cycles before surgery is contradictory.
P. I. Sorokin, D. O. Utkin, M. V. Novozhilov, Z. T. Abduragimova, S. E. Kulikova   +4 more
doaj   +1 more source

The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer

Annals of Surgical Oncology, 2020
Background Extent of tumor load is an important factor in the selection of ovarian cancer patients for cytoreductive surgery (CRS). The Peritoneal Cancer Index (PCI) gives exact information on tumor load but still is not standard in ovarian cancer ...
B. Jónsdóttir, M. Lomnytska, I. Poromaa, I. Silins, K. Stålberg   +4 more
semanticscholar   +1 more source

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

FEBS Open Bio, EarlyView.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi   +3 more
wiley   +1 more source

Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial

Nature Communications
Surgical removal of primary tumors reverses tumor-mediated immune suppression in pre-clinical models with metastatic disease. However, how cytoreductive surgery in the metastatic setting modulates the immune responses in patients, especially in the ...
Sangeeta Goswami, Jianjun Gao, Sreyashi Basu, Daniel D. Shapiro, Jose A. Karam, Rebecca Slack Tidwell, Kamran Ahrar, Matthew T. Campbell, Yu Shen, Alexandro E. Trevino, Aaron T. Mayer, Alexsandra B. Espejo, Christian Seua, Marc D. Macaluso, Yulong Chen, Wenbin Liu, Zhong He, Shalini S. Yadav, Ying Wang, Priya Rao, Li Zhao, Jianhua Zhang, Sonali Jindal, Nizar M. Tannir, Andrew Futreal, Linghua Wang, Padmanee Sharma   +26 more
doaj   +1 more source

Cytoreductive Surgery and Peritonectomy Procedures [PDF]

Indian Journal of Surgical Oncology, 2016
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has become widely accepted as an effective method of treating peritoneal metastases (PM) from various cancers. CRS performed with the goal of removing all the macroscopic disease and comprises of peritonectomy procedures and visceral resections.
Sanket S, Mehta, Aditi, Bhatt, Olivier, Glehen   +2 more
openaire   +2 more sources

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

International Journal of Cancer, EarlyView.
What's New? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman, Nahal Masrour, Naina Patel, Anna M. Piskorz, Robert Brown, James D. Brenton, Iain A. McNeish, James M. Flanagan   +7 more
wiley   +1 more source